Food intake 462
Food reward 98
Forgetting 307

G

GABA 155, 472
GABA uptake 444
Gastric lesions 472
Gerbils 284
Growth hormone 38, 85, 131
Guanfacine 171
Guinea pigs 404

H

Haloperidol 98, 125, 208, 253, 307, 338
Hamsters 444
Head-twitch responses 414
Heart rate 234
History 138
Homoeopathic drugs 338
Homovanillic acid 208
Housing conditions 31
Human 1
Human behavior 234
Human performance 198
Human subjects 8
Human visual system 177
Humans 261, 301
Hydantoin 278
6-Hydroxydopamine 244, 269
5-Hydroxytryptophan (5-HTP) 216
Hyperemotionality 472
Hyperphagia 462
Hypertension 20
Hypothermia 60

I

Imipramine 198, 253
^{3}H-imipramine 436, 456
Immobility 203
In vivo voltammetry 89
Insomnia 1
Instrumental response 8
Interresponse-time schedule 253
Interval therapy 1
Intracerebral infusion 311
Inverse agonist 113
Isapirone 382

J

Jump test 175

K

Ketanserine 14

L

Lateral ventricle 327
Learned tolerance 45
Lever press 69, 73
Lithium 138, 311
Locomotor activity 52, 221, 444, 449
Locus coeruleus 307
LSD 134

M

Magnetic fields 440
MAOI 134
Marijuana 234
5-HT-mediated behaviour 382
Memory 20, 55, 296, 334, 347, 360, 409
Memory retrieval 307
Meprobamate 14
Metabolites 404
Metergoline 388
Methocarbamol 98
Methodology 198
Methscopolamine 150
Methyl naltrexone 327
Metoclopramide 98
MHPG 38
Mianserin 360
Microstructural analysis 65
Microwave hyperthermia 45
Midazolam 183
Mood 432
Morphine 14, 60, 98, 175, 296, 323, 327
Motility 265
Motor activity 113, 364
Mouse 14, 52, 31, 171, 296, 334, 414
Mouse strain 60
Muscarinic 150
Muscle tension 230
Myoclonus 449

N

N. accumbens 77
N-allylnormetazocine 221
Naloxone 121, 261, 296, 323, 334
Naloxone binding 60
Narcotic antagonists 244
Neostigmine 150
Neuroendocrine 150
Neuroleptics 138, 265
Nicotine 14, 55, 105, 183
Nicotine chewing gum 230
Nicotine-gum 189
N-Methylspiperone 248
Nonreversal 355
Non-reward 155
Non-social behavior 31
Nootropic 378
Noradrenaline 414
Noradrenaline/5-hydroxytryptamine interactions 414
Nucleus accumbens 311, 340

O

8-OH-DPAT 467
Open-field 284
Operant responding 118
Opiates 409
Opioid analgesia 440
Opioid antagonism 221
Opioid peptides 409
Oxaprotiline 273
Oxotremorine 118

P

Pain threshold 409
Pain tolerance 409
Parkinson's disease 269
^{3}H-paroxetine 436
Partial reinforcement 239
Passive avoidance 296, 334
PCPA 467
Pentobarbitone 183
Pentylenetetrazol 14
Perception 230
Performance measures 395
Peripheral 5-HT 192, 216
Permethrin 278
PGD_2 121
Pharmacokinetics 404
Phasic hyperactivity 311
Phenacetin 14
Phencyclidine 14, 221, 334
Phenmetrazine 301
Phenobarbital 162
Phosphodiesterase inhibitor 273
Physostigmine 150, 334
Picrotoxin 183
Pigeons 323, 421
Pilocarpine 338
Pimozide 98
Piperonyl butoxide 278
Platelets 370, 456
Positron emission tomography 248
Pramiracetam 378
Prolactin 85, 131, 208, 388
Propranolol 20
Psychiatric patients 291
Psychological performance 347
Psychophysiological measures 395
Punished responding 125
Pyrazoloquinolines 462

R

Radial-arm maze 378
Radioreceptorassay 428
Rat 65, 69, 73, 98, 118, 125, 145, 162, 167, 183, 192, 203, 221, 253, 265, 273, 307, 311, 317, 355, 462, 467, 477
Rat brain 77
Rat neuronal membranes 436
Rate-dependency 73, 421
Reaction time 20, 198
Reasoning 198
5-HT_2 receptor function 382, 414
5-HT_{1A} receptor function 382
5-HT_{1B} receptor function 382
Recovery of function 449
Reference memory 378
Reinforcement 98
Renin-angiotensin system 192
Respiratory depression 60
Response choice 421
Response efficiency 69
Response rate 73
Response rates 69
Reversal 355
Reverse tolerance 221
Reward 327, 340
Ro 11-3128 462
Ro 11-3624 462
Ro 11-6896 284

Ro 15-1788 113, 183, 395, 462, 477
Rolipram 273
Rotational behavior 25, 269

S

SCH 23390 259
Schedule-controlled responding 323
Schedules of access 145
Schizophrenia 428
Scopolamine 94, 150, 175, 296, 347, 421
Sedation 360
Self-grooming 203
Sensitization 221
Serotonin 121, 134, 388, 467
Serotonin depletion 449
Serotonin syndrome 449
Serum levels 428
Sex differences 69, 73
Simultaneous brightness discrimination 355
Sleep 1
Smoking 189
Social behavior 234
Social behaviour 203
Social interaction 113
Speech 234
Staircase test 14
State-dependent learning 55, 105
Stereoisomers 221
Stereotypy 467
Stress 472
Stress-induced analgesia 440
Stretched attend posture 31
Striatum 25, 77
Stroop test 198
Subjective assessments 395
Subjective effects 301
Sulpiride 65, 125, 208
Switching 421

T

Temperature 284
/-Tetrahydropalmatine 89
TFMPP 134
Thioridazine 291
Thioridazine metabolites 291
Time-effect relations 8
Tolerance 45, 113, 118, 323
Tracazolate 14
Transdermal drug delivery 347
Trazodone 38
Tremor 278
Tricyclic antidepressants 171
Tryptophan 85
L-Tryptophan 1, 131
TVX Q 7821 382

U

Uptake 25
5HT uptake inhibitors 456

V

[Arg 8]-Vasopressin 69
Ventral tegmental area 65, 327
Verbal behavior 8

W

Working memory 378

X

Xylamidine 216

Y

Yawing 259
^{3}H-Yohimbine 370

Z

Zolpidem 317
Zuclopenthixol decanoate 428

Psychopharmacology

Volume 89 1986

	For North America and South America	For the rest of the world
	Clinical pharmacology	
Field editors:	D. Casey, Portland	J. Gerlach, Roskilde
Advisory editors:	L.E. Hollister, Palo Alto	P. Bech, Hillerød
	R.T. Jones, San Francisco	D.P. Bobon, Liège
	D. McNair, Boston	O. Lingjaerde, Tromsø
		E.S. Paykel, Cambridge
	Human experimental psychopharmacology	
Field editors:	J.O. Cole, Belmont	M. Hamilton, Leeds
Advisory editors:	C.E. Johanson, Chicago	A.R. Dabbs, Leeds
	T.O. Nelson, Seattle	I. Hindmarch, Leeds
	H.M. van Praag, New York	D.M. Warburton, Reading
	Biochemical neuropharmacology, drug metabolism and pharmacokinetics	
Field editors:	F. Sulser, Nashville	J. Leysen, Beerse
Advisory editors:	I. Kopin, Bethesda	C. Braestrup, Bagsvaerd
	J. Perel, Pittsburgh	H. Heykants, Beerse
	E. Sanders-Bush, Nashville	B. Scatton, Bagneux
	Behavioral pharmacology in laboratory animals	
Field editors:	H. Barry III, Pittsburgh	T.W. Robbins, Cambridge
Advisory editors:	J.B. Appel, Columbia	S.J. Cooper, Birmingham
	I. Hanin, Pittsburgh	A. Goudie, Liverpool
	H. Kalant, Toronto	B.J. Sahakian, Cambridge
	G.F. Koob, San Diego	I.P. Stolerman, London
	C. Kornetsky, Boston	
	V.G. Laties, Rochester	
	W.H. Morse, Boston	
	D.A. Overton, Philadelphia	
	Preclinical psychopharmacology	
Field editors:	S.D. Glick, Albany	A.R. Green, Oxford
Advisory editors:	D.B. Goldstein, Stanford	P. Jenner, London
	J. Harvey, Iowa City	D.H. Overstreet, Bedford Park
	T.G. Heffner, Ann Arbor	R.W. Russel, Bedford Park
	K.F. Killam, Davis	J. Scheel-Krüger, Roskilde
	K.A. Miczek, Medford	

Springer International

Psychopharmacology

This journal was founded as **Psychopharmacologia** in 1959 and was renamed **Psychopharmacology** beginning with Vol. 46 (1976).

The journal has been edited by the following Managing Editors:

Vol. 1 (1959), E. Rothlin and A. Wikler; Vol. 2 (1961), E. Rothlin and H. Isbell; Vol. 3 (1962), E. Rothlin and A. Wikler; Vol. 4 (1963)–Vol. 7 (1965), J.O. Cole and E. Rothlin; Vol. 8 (1965)–Vol. 16 (1969), J.O. Cole, E. Jacobsen, M.E. Jarvik, M. Shepherd; Vol. 17 (1970), J.O. Cole, E. Jacobsen, C. Kornetzky, M. Shepherd; Vol. 18 (1970)–Vol. 27 (1972), J.O. Cole, M. Hamilton, E. Jacobsen, C. Kornetzky; Vol. 28 (1973)–Vol. 35 (1974), J.O. Cole, M. Hamilton, E. Jacobsen, C. Kornetzky, R.W. Russell; Vol. 36 (1974)–Vol. 69 (1980), H. Barry III, J.O. Cole, M. Hamilton, E. Jacobsen, R.W. Russell. Vol. 70 (1980) – Vol. 77 (1982), H. Barry III, J.O. Cole, M. Hamilton, W. Robbins, R.W. Russell.

Starting with Vol. 80 (1983) the Editors have been: H. Barry III, T.W. Robbins (Coordinating Editors), J.O. Cole, J. Gerlach, M. Hamilton, J. Leysen, F. Sulser. As of Vol. 85 (1985): H. Barry III. D.E. Casey, J.O. Cole, J. Gerlach, S.D. Glick, A.R. Green, M. Hamilton, J. Leysen, T.W. Robbins, F. Sulser.

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review or thesis), that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.
All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.
The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA:
Photocopies may be made for personal or in-house use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. This fee is US $0.20 per page, or a minimum of US $1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0033-3185, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Other regulations:

Authors publishing in this journal can, under certain conditions, benefit from library and photocopy fees collected by VG WORT. Authors of German nationality and those resident in the Federal Republic of Germany or Berlin (West), as well as citizens of Austria, Switzerland and member countries of the European Community, may apply to Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Printers: Universitätsdruckerei H. Stürtz AG, Würzburg
© Springer-Verlag Berlin Heidelberg 1986
Springer-Verlag GmbH & Co. KG
1000 Berlin 33
Printed in Germany

Contents

Allen, E.M., see Jones, D.M., et al. 198

Anderson, I.M., Cowen, P.J.:
Clomipramine enhances prolactin and growth hormone responses to L-tryptophan 131

Andorn, A.C., see Piletz, J.E., et al. 370

Appel, J.B., see Cunningham, K.A., et al. 134

Axelsson, R., see Svensson, C., et al. 291

Bala, S.K., see Sukul, N.C., et al. 338

Bardo, M.T., Neisewander, J.L., Miller, J.S.:
Repeated testing attenuates conditioned place preference with cocaine 239

Barnes, J.C., Costall, B., Domeney, A.M., Naylor, R.J.:
Lithium and bupropion antagonise the phasic changes in locomotor activity caused by dopamine infused into the rat nucleus accumbens 311

Baum, S., see Hodges, H., et al. 155

Beck, C.H.M., Cooper, S.J.:
The effect of the β-carboline FG 7142 on the behaviour of male rats in a living cage: An ethological analysis of social and nonsocial behaviour 203

Belcher, M., see West, R.J., et al. 189

Benedikt, R.A., see Lukas, S.E., et al. 8

Benkelfat, C., see Poirier, M.F., et al. 456

Bhattacharya, S.K.:
The antinociceptive effect of intracerebroventricularly administered prostaglandin D_2 in the rat 121

Bhattacharyya, B., see Sukul, N.C., et al. 338

Block, D.R., see Russell, P.O., et al. 230

Blumenthal, J.A., see Madden, D.J., et al. 20

Bodnar, R.J., see Sperber, E.S., et al. 175

Bondesson, U., see Hartvig, P., et al. 248

Burki, H.R.:
Effects of fluperlapine on dopaminergic systems in rat brain 77

Burton, M.J., see Fletcher, P.J. 216

Burton, M.J., see Montgomery, A.M.J. 192

Cameron, D.F., see De Vane, C.L., et al. 404

Campbell, W., Clark, M.S.G., Mitchell, P.J., Needham, P.L., Semple, J.M.:
BRL 20596, a novel anilide with central dopamine antagonist activity 208

Carey, R.J.:
A conditioned anti-parkinsonian drug effect in the hemiparkinsonian rat 269

Carr, G.D., White, N.M.:
Anatomical disassociation of amphetamine's rewarding and aversive effects: An intracranial microinjection study 340

Carroll, B.A., see Cunningham, K.A., et al. 134

Cavicchini, E., see Ferri, S., et al. 244

Cekan, S., see Goiny, M., et al. 108

Chait, L.D., Uhlenhuth, E.H., Johanson, C.E.:
The discriminative stimulus and subjective effects of *d*-amphetamine, phenmetrazine and fenfluramine in humans 301

Charney, D.S., see Price, L.H., et al. 38

Chen, P., see Herr, D.W., et al. 278

Clark, M.S.G., see Campbell, W., et al. 208

Clemmesen, L., see Ulrichsen, J., et al. 162

Cooper, S.J., Yerbury, R.E.:
Benzodiazepine-induced hyperphagia: Stereospeciticity and antagonism by pyrazoloquinolines, CGS 9895 and CGS 9896 462

Cooper, S.J., see Beck, C.H.M. 203

Cooper, S.J., see Estall, L.B. 477

Corrigall, W.A., Linseman, M.A., D'Onofrio, R.M., Lei, H.:
An analysis of the paradoxical effect of morphine on runway speed and food consumption 327

Costa, C., see Schulz, P., et al. 293

Costall, B., see Barnes, J.C., et al. 311

Cowen, P.J., see Anderson, I.M. 131

Cunningham, K.A., Carroll, B.A., Appel, J.B.:
Effects of repeated administration of the monoamine oxidase inhibitor phenelzine on the discriminability of *d*-lysergic acid diethylamide (LSD) and 1-(*m*-trifluoromethylphenyl) piperazine (TFMPP) 134

Curran, H.V., Shine, P., Lader, M.:
Effects of repeated doses of fluvoxamine, mianserin and placebo on memory and measures of sedation 360

Curzon, G., see Dourish, C.T., et al. 467

Dall'Olio, R., see Vaccheri, A., et al. 265

Davies, C.L., see Heal, D.J., et al. 414

De Souza, R.J., see Goodwin, G.M., et al. 382

De Vane, C.L., Laizure, S.C., Cameron, D.F.:
The effect of experimentally-induced renal failure on accumulation of bupropion and its major basic metabolites in plasma and brain of guinea pigs 404

Di Chiara, G., see Morelli, M., et al. 259

Dick, P., see Schulz, P., et al. 293

Dingemanse, J., see File, S.E., et al. 113

Domeney, A.M., see Barnes, J.C., et al. 311

D'Onofrio, R.M., see Corrigall, W.A., et al. 327

Dourish, C.T., Hutson, P.H., Curzon, G.:
Para-chlorophenylalanine prevents feeding induced by the serotonin agonist 8-hydroxy-2-(di-*n*-propylamino) tetralin (8-OH-DPAT) 467

Dunne, M.P., Hartley, L.R.:
Scopolamine and the control of attention in humans 94

Eckernäs, S.Å., see Hartvig, P., et al. 248

Ekblom, B., see Hartvig, P., et al. 248

Ekelund, L.-G., see Madden, D.J., et al. 20

Epstein, L.H., see Russell, P.O., et al. 230

Estall, L.B., Cooper, S.J.:
Benzodiazepine receptor-mediated effect of CGS 8216 on milk consumption in the non-deprived rat 477

Evenden, J.L.:
Contrasting baseline-dependent effects of amphetamine, chlorpromazine and scopolamine on response switching in the pigeon 421

Feldon, J., see Weiner, I. 355

Ferri, S., Cavicchini, E., Romualdi, P., Speroni, E., Murari, G.:
Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of *Cannabis sativa L.* 244

Fibiger, H.C., see Murray, C.L. 378

File, S.E., Dingemanse, J., Friedman, H.L., Greenblatt, D.J.:
Chronic treatment with Ro 15-1788 distinguishes between its benzodiazepine antagonist, agonist and inverse agonist properties 113

Flachs, H., see Ulrichsen, J., et al. 162

Fletcher, P.J., Burton, M.J.:
Dissociation of the anorectic actions of 5-HTP and fenfluramine 216

Fonagy, P., see Higgitt, A., et al. 395

Friedman, H.L., see File, S.E., et al. 113

Furukawa, H., see Nabeshima, T., et al. 334

Galzin, A.M., see Poirier, M.F., et al. 456

Gandolfi, O., see Vaccheri, A., et al. 265

Garcha, H.S., see Stolerman, I.P., et al. 183

Gelbtuch, M.H., see Harris, J.P., et al. 177

Glick, S.D., see Shapiro, R.M., et al. 25

Goiny, M., Uvnäs-Moberg, K., Cekan, S.:
Bromocriptine and apomorphine stimulation of cortisol secretion in conscious dogs; evidence for a stimulatory site located outside the blood brain barrier 108

Gonon, F., see Marcenac, F., et al. 89

Goodwin, G.M., De Souza, R.J., Green, A.R.:
The effects of a 5-HT_1 receptor ligand isapirone (TVX Q 7821) on 5-HT synthesis and the behavioural effects of 5-HT agonists in mice and rats 382

Green, A.R., see Goodwin, G.M., et al. 382

Green, S., see Hodges, H., et al. 155

Greenblatt, D.J., see File, S.E., et al. 113

Griffiths, A.N., see Jones, D.M., et al. 198

Griffiths, R.R., see Nemeth-Coslett, R. 261

Hajek, P., see West, R.J., et al. 189

Halaris, A., see Piletz, J.E., et al. 370

Halldin, C., see Hartvig, P., et al. 248

Hara, T., see Ushijima, I., et al. 472

Harris, J.P., Gelbtuch, M.H., Phillipson, O.T.:
Effects of haloperidol and nomifensine on the visual aftereffects of tilt and movement 177

Harry, G.J., see Herr, D.W., et al. 278

Hartley, L.R., see Dunne, M.P. 94

Hartvig, P., Eckernäs, S.Å., Lindström, L., Ekblom, B., Bondesson, U., Lundqvist, H., Halldin, C., Någren, K., Långström, B.:
Receptor binding of N-(methyl-^{11}C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET) 248

Haskett, R.F., see Träskman-Bendz, L., et al. 85

Heal, D.J., Philpot, J., O'Shaughnessy, K.M., Davies, C.L.:
The influence of central noradrenergic function on 5-HT_2-mediated head-twitch responses in mice: Possible implications for the actions of antidepressant drugs 414

Heinsbroek, R.P.W., see van Haaren, F., et al. 69

Heinsbroek, R.P.W., see van Haaren, F., et al. 73

Hemmingsen, R., see Ulrichsen, J., et al. 162

Heninger, G.R., see Price, L.H., et al. 38

Herr, D.W., Hong, J.-S., Chen, P., Tilson, H.A., Harry, G.J.:
Pharmacological modification of DDT-induced tremor and hyperthermia in rats: Distributional factors 278

Higgins, S.T., Stitzer, M.L.:
Acute marijuana effects on social conversation 234

Higgitt, A., Lader, M., Fonagy, P.:
The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects 395

Hiltunen, A.J., Järbe, T.U.C.:
Discrimination of Ro 11-6896, chlordiazepoxide and ethanol in gerbils: Generalization and antagonism tests 284

Hjeresen, D.L., Reed, D.R., Woods, S.C.:
Tolerance to hypothermia induced by ethanol depends on specific drug effects 45

Hodges, H., Baum, S., Taylor, P., Green, S.:
Behavioural and pharmacological dissociation of chlordiazepoxide effects on discrimination and punished responding 155

Hong, J.-S., see Herr, D.W., et al. 278

Hough, L.B., see Shapiro, R.M., et al. 25

Howard, J.L., see Pollard, G.T. 14

Howard, J.L., see Pollard, G.T. 253

Huey, L., see Janowsky, D.S., et al. 150

Hutson, P.H., see Dourish, C.T., et al. 467

Iwamoto, E.T.:
Comparison of the pharmacologic effects of N-allylnormetazocine and phencyclidine: Sensitization, cross-sensitization, and opioid antagonist activity 221

Jacobsen, E.:
The early history of psychotherapeutic drugs 138

Jamal, O.S., see Overstreet, D.H. 118

James, M., see Warburton, D.M., et al. 55

Janowsky, D.S., Risch, S.C., Kennedy, B., Ziegler, M., Huey, L.:
Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release 150

Järbe, T.U.C., see Hiltunen, A.J. 284

Johanson, C.E., see Chait, L.D., et al. 301

Jones, D.M., Allen, E.M., Griffiths, A.N., Marshall, R.W., Richens, A.:
Human cognitive function following binedaline (50 mg and 100 mg) and imipramine (75 mg): Results with a new battery on tests 198

Jones, D.M., see Miles, C., et al. 432

Kaesermann, H.P.:
Stretched attend posture, a non-social form of ambivalence, is sensitive to a conflict-reducing drug action 31

Kameyama, T., see Nabeshima, T., et al. 334

Karczag, I., see Székely, J.I., et al. 409

Kato, R., see Muraki, T. 60

Katz, J.L.:
Tolerance to effects of morphine without cross tolerance to effects of clonidine on schedule-controlled behavior of pigeons 323

Kavaliers, M., Ossenkopp, K.P.:
Stress-induced opioid analgesia and activity in mice: Inhibitory influences of exposure to magnetic fields 440

Kennedy, B., see Janowsky, D.S., et al. 150

Kozawa, T., see Nabeshima, T., et al. 334

Krantz, D.S., see Madden, D.J., et al. 20

Kudo, R., see Ushijima, I., et al. 472

Kulkarni, S.K., see Parale, M.P. 171

Lader, M., see Curran, H.V., et al. 360

Lader, M., see Higgitt, A., et al. 395

Langer, S.Z., see Poirer M.-F., et al. 456

Laizure, S.C., see De Vane, C.L., et al. 404

Långström, B., see Hartvig, P., et al. 248

Lei, H., see Corrigall, W.A., et al. 327

Light, K.C., see Madden, D.J., et al. 20

Lindström, L., see Hartvig, P., et al. 248

Linseman, M.A., see Corrigall, W.A., et al. 327

Lipska, B., see Szukalski, B., et al. 429

Longoni, R., see Morelli, M., et al. 259

Loo, H., see Poirier, M.F., et al. 456

Louwerse, A., see van Haaren, F., et al. 69

Louwerse, A., see van Haaren, F., et al. 73

Lowe, G.:
State-dependent learning effects with a combination of alcohol and nicotine 105

Lukas, S.E., Mendelson, J.H., Benedikt, R.A.:
Instrumental analysis of ethanol-induced intoxication in human males 8

Lundqvist, H., see Hartvig, P., et al. 248

Madden, D.J., Blumenthal, J.A., Ekelund, L.-G., Krantz, D.S., Light, K.C., McKee, D.C.:
Memory performance by mild hypertensives following beta-adrenergic blockade 20

Marcenac, F., Zhang Jin, G., Gonon, F.:
Effect of *l*-tetrahydropal-matine on dopamine release and metabolism in the rat striatum 89

Marcucella, H., Munro, I.:
Patterns of ethanol and water consumption as a function of restricted ethanol access and feeding condition 145

Marshall, R.W., see Jones, D.M., et al. 198

Mårtensson, E., see Svensson, C., et al. 291

McKee, D.C., see Madden, D.J., et al. 20

Meisburger, J.G., see Ortmann, R. 273

Mellerup, E.T., Plenge, P.:
High affinity binding of ^{3}H-paroxetine and ^{3}H-imipramine to rat neuronal membranes 436

Mendelson, J.H., see Lukas, S.E., et al. 8

Miles, C., Porter, K., Jones, D.M.:
The interactive effects of alcohol and mood on dual-task performance 432

Miller, J.S., see Bardo, M.T., et al. 239

Mitchell, P.J., see Campbell, W., et al. 208

Mizuki, Y., see Ushijima, I., et al. 472

Montanaro, N., see Vaccheri, A., et al. 265

Montgomery, A.M.J., Burton, M.J.:
Pharmacological investigations of the mechanisms underlying the effects of peripheral 5-HT on flavour consumption and preference 192

Morelli, M., Longoni, R., Spina, L., Di Chiara, G.:
Antagonism of apomorphine-induced yawning by SCH 23390: Evidence against the autoreceptor hypothesis 259

Mueller, E.A., Murphy, D.L., Sunderland, T.:
Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans 388

Munro, I., see Marcucella, H. 145

Muraki, T., Kato, R.:
Strain difference in the effects of morphine on the rectal temperature and respiratory rate in male mice 60

Murari, G., see Ferri, S., et al. 244

Murphy, D.L., see Mueller, E.A., et al. 388

Murray, C.L., Fibiger, H.C.:
The effect of pramiracetam (C1-879) on the aquisition of a radial arm maze task 378

Muscat, R., see Towell, A., et al. 65

Nabeshima, T., Kozawa, T., Furukawa, H., Kameyama, T.:
Phencyclidine-induced retrograde amnesia in mice 334

Någren, K., see Hartvig, P., et al. 248

Naylor, R.J., see Barnes, J.C., et al. 311

Needham, P.L., see Campbell, W., et al. 208

Neisewander, J.L., see Bardo, M.T., et al. 239

Nemeth-Coslett, R., Griffiths, R.R.:
Naloxone does not affect cigarette smoking 261

Nurowska, K., see Szukalski, B., et al. 429

Nyberg, G., see Svensson, C., et al. 291

Ortmann, R., Meisburger, J.G.:
Rolipram forms a potent discriminative stimulus in drug discrimination experiments in rats 273

O'Shaughnessy, K.M., see Heal, D.J., et al. 414

Ossenkopp, K.P., see Kavaliers, M. 440

Overstreet, D.H., Jamal, O.S.:
Behavioural tolerance to arecoline in rats: Cross-tolerance to oxotremorine and prevention by pretreatment with atropine 118

Parale, M.P., Kulkarni, S.K.:
Clonidine – induced behavioural despair in mice: Reversal by antidepressants 171

Parrott, A.C.:
The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance 347

Phillipson, O.T., see Harris, J.P., et al. 177

Philpot, J., see Heal, D.J., et al. 414

Pich, E.M., Samanin, R.:
Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: Possible role of dopamine 125

Piletz, J.E., Andorn, A.C., Halaris, A.:
^{3}H-clonidine and ^{3}H-yohimbine binding to glass fiber filters: Implications for studies with platelet membranes 370

Pirkle, W.H., see Smith, D.F. 392

Plenge, P., see Mellerup, E.T. 436

Poirier, M.-F., Benkelfat, C., Loo, H., Sechter, D., Zarifian, E., Galzin, A.M., Langer, S.Z.:
Reduced B_{max} of [^{3}H]-imipramine binding to platelets of depressed patients free of previous medication with 5HT uptake inhibitors 456

Pollard, G.T., Howard, J.L.:
Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time >72-s schedule 253

Pollard, G.T., Howard, J.L.:
The staircase test: Some evidence of nonspecificity for anxiolytics 14

Porter, K., see Miles, C., et al. 432

Potegal, M.:
Differential effects of ethyl (R,S)-nipecotate on the behaviors of highly and minimally aggressive female golden hamsters 444

Pranzatelli, M.R., Snodgrass, S.R.:
Enhanced selective 5-HT depletions in the DHT rat model: Denervation supersensitivity and recovery of function 449

Price, L.H., Charney, D.S., Heninger, G.R.:
Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients 38

Reed, D.R., see Hjeresen, D.L., et al. 45

Renzi, P., see Sansone, M., et al. 52

Richens, A., see Jones, D.M., et al. 198

Risch, S.C., see Janowsky, D.S., et al. 150

Romero, M.-T., see Sperber, E.S., et al. 175

Romualdi, P., see Ferri, S., et al. 244

Rose, I.C., see Stolerman, I.P., et al. 183

Rush, D.K.:
Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone 296

Russell, P.O., Epstein, L.H., Sittenfield, S.L., Block, D.R.:
The effects of nicotine chewing gum on the sensitivity to muscle tension 230

Samanin, R., see Pich, E.M. 125

Sanger, D.J.:
Response decrement patterns after neuroleptic and non-neuroleptic drugs 98

Sanger, D.J., Zivkovic, B.:
The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic 317

Sansone, M., Renzi, P., Vetulani, J.:
Facilitation of stimulatory effect of chlordiazepoxide-amphetamine combination by subacute administration of chlordiazepoxide in mice 52

Sara, S.J.:
Haloperidol facilitates memory retrieval in the rat 307

Schneider-Helmert, D., Spinweber, C.L.:
Evaluation of L-tryptophan for treatment of insomnia: A review 1

Schulz, P., Costa, C., Widmer, J., Dick, P.:
Influence of the time of administration of dexamethasone 0.25 MG on cortisol secretion in normal humans 293

Sechter, D., see Poirier, M.F., et al. 456

Semple, J.M., see Campbell, W., et al. 208

Shapiro, R.M., Glick, S.D., Hough, L.B.:
Striatal dopamine uptake asymmetries and rotational behavior in unlesioned rats: revising the model? 25

Shergold, K., see Warburton, D.M., et al. 55

Shine, P., see Curran, H.V., et al. 360

Sittenfield, S.L., see Russell, P.O., et al. 230

Smith, D.F., Pirkle, W.H.:
Stereoselective analysis of racemic psychotropic compounds by HPLC on chiral stationary phase 392

Snodgrass, S.R., see Pranzatelli, M.R. 449

Sokomba, E., see Wambebe, C. 167

Sperber, E.S., Romero, M.-T., Bodnar, R.J.:
Selective potentiations in opioid analgesia following scopolamine pretreatment 175

Speroni, E., see Ferri, S., et al. 244

Spina, L., see Morelli, M., et al. 259

Spinweber, C.L., see Schneider-Helmert, D. 1

Spoerlein, M.T., see Wilmot, C.A., et al. 364

Stitzer, M.L., see Higgins, S.T. 234

Stolerman, I.P., Garcha, H.S., Rose, I.C.:
Midazolam cue in rats: effects of Ro 15-1788 and picrotoxin 183

Sukul, N.C., Bala, S.K., Bhattacharyya, B.:
Prolonged cataleptogenic effects of potentized homoeopathic drugs 338

Sunderland, T., see Mueller, E.A., et al. 388

Svensson, C., Nyberg, G., Axelsson, R., Mårtensson, E.:
Concentrations of thioridazine and thioridazine metabolites in erythrocytes 291

Székely, J.I., Török, K., Karczag, I., Tolna, J., Till, M.:
Effects of D-Met^2, Pro^5-enkephalinamide on pain tolerance and some cognitive functions in man 409

Szukalski, B., Lipska, B., Welbel, L., Nurowska, K.:
Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate 429

Taylor, P., see Hodges, H., et al. 155

Till, M., see Székely, J.I., et al. 409

Tilson, H.A., see Herr, D.W., et al. 278

Tolna, J., see Székely, J.I., et al. 409

Török, K., see Székely, J.I., et al. 409

Towell, A., Muscat, R., Willner, P.:
Apomorphine anorexia: The role of dopamine cell body autoreceptors 65

Träskman-Bendz, L., Haskett, R.F., Zis, A.P.:
Neuroendocrine effects of L-tryptophan and dexamethasone 85

Uhlenhuth, H.E., see Chait, L.D., et al. 301

Ulrichsen, J., Clemmesen, L., Flachs, H., Hemmingsen, R.:
The effect of phenobarbital and carbamazepine on the ethanol withdrawal reaction in the rat 162

Ushijima, I., Mizuki, Y., Hara, T., Kudo, R., Watanabe, K., Yamada, M.:
The role of adenosinergic, GABAergic and benzodiazepine systems in hyperemotionality and ulcer formation in stressed rats 472

Uvnäs-Moberg, K., see Goiny, M., et al. 108

Vaccheri, A., Dall'Olio, R., Gandolfi, O., Montanaro, N.:
Involvement of different dopamine receptors in rat diphasic motility response to apomorphine 265

van de Poll, N.E., see van Haaren, F., et al. 69

van de Poll, N.E., see van Haaren, F., et al. 73

van Haaren, F., Heinsbroek, R.P.W., Louwerse, A., van de Poll, N.E.:
d-Amphetamine differentially affects low, but not high response rates of male and female Wistar rats 69

van Haaren, F., Heinsbroek, R.P.W., Louwerse, A., van de Poll, N.E.:
Vasopressin has general rate-decreasing effects on schedules maintaining either high or low response rates 73

VanderWende, C., see Wilmot, C.A., et al. 364

Vetulani, J., see Sansone, M., et al. 52

Wambebe, C., Sokomba, E.:
Some behavioural and EEG effects of ascorbic acid in rats 167

Warburton, D.M., Wesnes, K., Shergold, K., James, M.:
Facilitation of learning and state dependency with nicotine 55

Watanabe, K., see Ushijima, I., et al. 472

Weiner, I., Feldon, J.:
Reversal and nonreversal shifts under amphetamine 355

Welbel, L., see Szukalski, B., et al. 429

Wesnes, K., see Warburton, D.M., et al. 55

West, R.J., Hajek, P., Belcher, M.:
Which smokers report most relief from craving when using nicotine chewing gum? 189

White, N.M., see Carr, G.D. 340

Widmer, J., see Schulz, P., et al. 293

Willner, P., see Towell, A., et al. 65

Wilmot, C.A., VanderWende, C., Spoerlein, M.T.:
Behavioral and biochemical studies of dopamine receptor sensitivity in differentially housed mice 364

Woods, S.C., see Hjeresen, D.L., et al. 45

Yamada, M., see Ushijima, I., et al. 472

Yerbury, R.E., see Cooper, S.J. 462

Zarifian, E., see Poirier, M.F., et al. 456

Zhang Jin, G., see Marcenac, F., et al. 89

Ziegler, M., see Janowsky, D.S., et al. 150

Zis, A.P., see Träskman-Bendz, L., et al. 85

Zivkovic, B., see Sanger, D.J. 317

This volume includes a supplement with the abstracts of the inaugural meeting of the European Behavioural Pharmacology society and satellite workshop on Transduction Mechanisms of Drug Stimuli, July 2–7, 1986, Antwerp and Beerse, Belgium 51–557

Indexed in *Current Contents*